Shanghai Huilun Life Science & Technology Co. Ltd.

Primary Objectives: * To evaluate the effect of repeated oral administration of fluconazole (a CYP2C9 intermediate-acting inhibitor) on the pharmacokinetics (PK) of HL-1186 in healthy adult trial participants; * To evaluate the effect of repeated oral administration of rifampin (a CYP2C9 intermediate-acting inducer) on the PK of HL-1186 in healthy adult trial participants; * To evaluate the effect of repeated oral administration of HL-1186 on the PK of midazolam (a CYP3A4 substrate) and its major metabolite 1-OH midazolam in healthy adult trial participants; * To evaluate the interaction between repeated oral administration of HL-1186 and metformin on the PK of healthy adult trial participants. Secondary Objectives: * To evaluate the PK characteristics of HL-1186 and its major metabolite HL-1192 after monotherapy or combination therapy in healthy adult trial participants; * Evaluate the effects of repeated oral administration of fluconazole (a CYP2C9 intermediate-acting inhibitor), rifampin (a CYP2C9 intermediate-acting inducer), and metformin on the pharmacokinetic (PK) of HL-1186's major metabolite, HL-1192, in healthy adult trial participants; Evaluate the effects of HL-1186 on other PK parameters of midazolam and its major metabolite 1-OH midazolam, and metformin in healthy adult trial participants; Evaluate the safety and tolerability of HL-1186 as a monotherapy or in combination therapy in healthy adult trial participants.